- Home
- NPCT vs IMMP Comparison
NPCT vs IMMP Comparison
Compare NPCT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- IMMP
- Stock Information
- Founded
- NPCT 2020
- IMMP 1987
- Country
- NPCT United States
- IMMP Australia
- Employees
- NPCT N/A
- IMMP N/A
- Industry
- NPCT Investment Managers
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- IMMP Health Care
- Exchange
- NPCT Nasdaq
- IMMP Nasdaq
- Market Cap
- NPCT 311.7M
- IMMP 304.0M
- IPO Year
- NPCT N/A
- IMMP N/A
- Fundamental
- Price
- NPCT $10.68
- IMMP $1.85
- Analyst Decision
- NPCT
- IMMP Buy
- Analyst Count
- NPCT 0
- IMMP 2
- Target Price
- NPCT N/A
- IMMP $8.50
- AVG Volume (30 Days)
- NPCT 107.1K
- IMMP 74.2K
- Earning Date
- NPCT 01-01-0001
- IMMP 03-25-2025
- Dividend Yield
- NPCT 9.82%
- IMMP N/A
- EPS Growth
- NPCT N/A
- IMMP N/A
- EPS
- NPCT N/A
- IMMP N/A
- Revenue
- NPCT N/A
- IMMP $3,019,249.00
- Revenue This Year
- NPCT N/A
- IMMP N/A
- Revenue Next Year
- NPCT N/A
- IMMP $20.28
- P/E Ratio
- NPCT N/A
- IMMP N/A
- Revenue Growth
- NPCT N/A
- IMMP 24.11
- 52 Week Low
- NPCT $8.58
- IMMP $1.65
- 52 Week High
- NPCT $10.63
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- NPCT 39.68
- IMMP 48.75
- Support Level
- NPCT $10.76
- IMMP $1.65
- Resistance Level
- NPCT $10.96
- IMMP $1.88
- Average True Range (ATR)
- NPCT 0.11
- IMMP 0.09
- MACD
- NPCT -0.03
- IMMP 0.01
- Stochastic Oscillator
- NPCT 7.00
- IMMP 65.00
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.